Clinical Studies

Unlike many cosmetics, the safety and efficacy of the SEQuaderma® skin care products have been tested in a number of robust dermatology and cosmetic studies. The safety of the Sequessome Technology® products is shown by studies involving thousands of patients in a range of conditions. In dermatology, to date more than 700 subjects have used SEQuaderma products in formal studies, which are summarised below. Individual data summaries can be found on the Study Summaries page. All these data reinforce the excellent safety of these products and demonstrate meaningful efficacy against the key symptoms in the skin conditions tested. All except the most recent data have been published in peer-reviewed journals or presented at medical congresses.

Please also follow the links to learn more about how SEQuaderma is different and why it is recommended to your patients and customers to improve their skin health and overall wellbeing as a safe alternative to prescribed medicine and other OTC treatments.

Study Design Subjects/patients Key Efficacy Findings Key Safety Findings
Rosacea (click to download)
Multicentre, randomised, placebo-controlled study comparing 4 weeks of SEQuaderma Redness Prone Skin1 61 patients with mild, moderate or severe type 1 rosacea (40 on active treatment, 21 on placebo) Significant improvements in background redness, flushing and thread veins with SEQuaderma. Nearly 80% reported improvements in a primary or secondary symptom of rosacea after 4 weeks. Efficacy continued to develop between 2 and 4 weeks Well tolerated; no serious treatment-related AEs
A 4-week study of the use of SEQuaderma Redness Prone Skin2 101 healthy subjects who suffer from facial redness (background and flushing) completing self-assessment after 4 weeks’ use of SEQuaderma 63% of subjects reported reduced flushing frequency and the majority stated a reduced occurrence and intensity of visible blushing. 73% of subjects reported reduced blood vessel appearance. The majority of users agreed the product was the most effective anti-redness serum they had used and they would buy this product instead of their usual product Well tolerated; no AEs reported
Eczema (click to download)
Multicentre, randomised study examining 3 weeks’ treatment with SEQuaderma3 49 patients with mild-to-moderate atopic eczema, dyshidrotic hand eczema or seborrhoeic eczema treated with SEQuaderma All assessments (investigator, patient and disease-specific scores) showed symptom improvements after 3 weeks’ treatment. More than 70% of patients reported improvements in their symptoms Well tolerated; no serious treatment-related AEs
Acne (click to download)
Multicentre, randomised study examining 3 weeks’ treatment with SEQuaderma Acne Prone Skin3 17 patients with acne vulgaris treated with SEQuaderma All assessments (investigator, patient and disease-specific scores) showed symptom improvements after 3 weeks’ treatment. More than 80% of patients reported an improvement in their condition Well tolerated; no serious treatment-related AEs
Study comparing 3 weeks of SEQuaderma with placebo4 224 healthy volunteers with self-assessed oily and spot-prone skin. 37 randomised to SEQuaderma, 20 to placebo and 102 to an alternative test formulation (plus 65 for subjective assessment only) Significant reductions in sebum levels (>50%), in the number of blocked pores (>80%) and pustules (>98%) with 3 weeks’ treatment with SEQuaderma versus placebo Well tolerated; no AEs reported
Seborrhoeic dermatitis (click to download)
Multicentre, randomised study examining 3 weeks’ treatment with SEQuaderma3 14 patients with seborrhoeic dermatitis treated with SEQuaderma More than 85% of patients had improvements in their symptoms, as assessed by their doctors. Of these, around 20% were judged to be clear of symptoms. Nearly 80% of patients reported that they could see or feel the improvements in their symptoms Well tolerated; no serious treatment-related AEs
Ageing and thinning skin (click to download)
Home-use study investigating the subjective and objective effects of 12 weeks’ treatment with SEQuaderma Ageing Thinning Skin5 30 healthy subjects with skin affected by chronological and photo-ageing (all on active treatment) 100% of users had significant measured reduction in wrinkles. Users saw 80–100% improvement across all 10 tested signs of photoageing. 80% of consumers claimed looking between 5 to 10 years younger after 8 weeks Well tolerated; no AEs reported
Home-use study assessed the efficacy and safety of SEQuaderma versus placebo or the UK market leader in healthy women with wrinkled aged skin6 90 healthy subjects were recruited to the objective assessment study of which 84 completed the 8 weeks (27 on SEQuaderma, 28 on placebo and 29 on the comparator). An additional 70 subjects completed subjective assessments only, all using active SEQuaderma 8 weeks’ treatment with SEQuaderma gave equivalent effects on measured wrinkle volume and wrinkle appearance as the UK market leader, and both were significantly better than placebo. Users rated SEQuaderma Ageing Thinning Skin as higher than the comparator (market leader), with 99% of respondents claiming they would buy it in place of their usual anti-ageing serum Well tolerated; no AEs reported
Uneven skin tone
A 6-week study of the use of SEQuaderma Uneven Skin Tone 7 110 healthy subjects who suffer from skin pigmentation of melanic origin (including melasma or chloasma spots, uneven skin tone, age, sun or liver spots, freckles, post-inflammatory hyperpigmentation or dark circles) completing self-assessment after 6 weeks’ use of SEQuaderma 100% of users had significant measured reduction in wrinkles. Users saw 80–100% improvement across all 10 tested signs of photoageing. 80% of consumers claimed looking between 5 to 10 years younger after 8 weeks Well tolerated; no AEs reported

1 Luger T, et al. A multicentre, randomized, placebo-controlled trial establishing the treatment effect of TDT 068, a topical formulation containing drug-free ultra-deformable phospholipid vesicles, on the primary features of erythematotelangiectatic rosacea. J Eur Acad Dermatol Venereol 2015;29:283–290.

2 Princeton Consumer Research Report; PROUSE1, 29 May 2015.

3 Luger T, et al. Both ketoprofen in transfersome (IDEA-070) and drug-free vehicle (TDT 070) improved symptoms in patients with inflammatory skin conditions. J Invest Dermatol 2013;133:S159–S190.

4 Princeton Consumer Research Report; PROSEB1, 4 May 2015.

5 Princeton Consumer Research Report; PROAWR1, 11 February 2015.

6 Princeton Consumer Research Report; PROAWR2, 22 May 2015.

7 Princeton Consumer Research Report; PROUSE4, 13 Nov 2015.